Clearinghouse

Clearignhouse

In this section you can log in on the Clearinghouse and submit your HIV/AIDS good practice materials. You can also edit or delete your previous uploads.

AFEW International Report "Interruption and Innovation"

AFEW International released the COVID-19 report “Interruption and Innovation” with an overview of disruptions of and responses to prevention, treatment and care for key populations at risk for HIV, TB and viral hepatitis due to Covid-19 in Eastern Europe and Central Asia.

The purpose of this document, commissioned by AFEW International, is to provide an overview of the impact of the pandemic with the novel coronavirus (SARS-CoV-2) and its associated disease, COVID-19, on the continuity of prevention, treatment and care of HIV, Tuberculosis, viral hepatitis and other relevant diseases in Eastern Europe and Central Asia (EECA).

The regional scope of this report includes the countries Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.

This report will pay special attention to the impact of measures to prevent COVID-19 on disruptions of services for key- and vulnerable populations to the diseases mentioned earlier. These key- and vulnerable populations are: people who inject drugs, sex workers, men who have sex with men, trans people, people living with HIV, people deprived of liberty like people in prison or pre-trial detention, tuberculosis patients and their contacts, labour migrants, refugees and internally displaced people.

Year
2020
  • Central Asia
  • Eastern Europe
  • Advocacy
  • Affordability
  • Capacity building
  • Care and support
  • Co-infections
  • Epidemiology
  • Gender
  • Harm reduction
  • Human rights
  • Inequalities in health
  • Laws and regulations
  • Legislation
  • Media
  • Migration
  • Monitoring and Evaluation
  • Policy
  • Pre-exposure prophylaxis (PrEP)
  • Prevention
  • Resource mobilisation
  • Sexual and reproductive health
  • STI's
  • Stigma and discrimination
  • Testing and counselling
  • Treatment
  • Treatment as prevention (TasP)
  • Tubercolosis
  • Viral hepatitis
  • Health care professionals
  • NGOs
  • Policy makers

Tweeter news
@aidsactioneurop